GLUE
Monte Rosa Therapeutics Inc
NASDAQ · Biotechnology
$19.55
+0.65 (+3.44%)
Open$19.27
Previous Close$18.90
Day High$20.29
Day Low$19.10
52W High$25.77
52W Low$3.50
Volume—
Avg Volume1.11M
Market Cap1.49B
P/E Ratio71.16
EPS$0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+96.7% upside
Current
$19.55
$19.55
Target
$38.45
$38.45
$28.40
$38.45 avg
$50.36
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 78.01M | 401.98M | 400.93M |
| Net Income | -74,992,375 | -29,192,444 | -34,329,564 |
| Profit Margin | -96.1% | -7.3% | -8.6% |
| EBITDA | -75,297,346 | -51,685,540 | -47,809,490 |
| Free Cash Flow | — | -50,874,519 | -44,333,819 |
| Rev Growth | — | +22.8% | -9.2% |
| Debt/Equity | — | 0.43 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |